Large study finds risks of liver cancer low for certain PSC patients
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…
Cholangitis
PPAR agonists effective in UDCA-resistant primary biliary cholangitis
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…
Umecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Imbalance of certain fatty molecules may signal disease severity in PSC
An imbalance in the blood between long-chain and very long-chain ceramides — fatty molecules that help fine-tune the body’s inflammatory response — may help indicate…
Nearly half of PBC patients in US haven’t seen a specialist recently
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
EMA to review linerixibat for itch in primary biliary cholangitis
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).
Mononucleosis linked to higher risk of developing PSC: Study
People who have experienced mononucleosis, or mono, which is caused by an infection of the Epstein-Barr virus (EBV), are 12 times more likely to develop…
Trial of golexanolone for PBC cognitive symptoms to resume
A Phase 1b/2a clinical trial of golexanolone, Umecrine Cognition’s candidate therapy for cognitive symptoms and fatigue related to primary biliary cholangitis (PBC), will resume…
FDA to review linerixibat for PBC-related itching
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
30% rise due in primary sclerosing cholangitis prevalence by 2040
The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…
